Literature DB >> 17684715

[Adrenal gland tumors].

H S Willenberg1, D Zschucke, S R Bornstein.   

Abstract

Adrenal masses are one of the most common tumors in humans. They are a very heterogenous group of diseases and include benign and malignant adrenocortical lesions, metastases, pheochromocytomas and other entities. Adrenal masses originating from steroidogenic or chromaffin cells may be silent or the source of subclinical or overt hormone excess, such as primary aldosteronism, hypercortisolism or symptomatic catecholamine excess. On the other hand, adrenal hyperplasia may be the result of excess ACTH secretion in steroid biosynthesis disorders with deficient glucocorticoid secretion, in glucocorticoid resistance, in Cushing's disease, or ectopic ACTH syndrome. Algorithms for endocrine testing, imaging studies and their combination are available for defining the tumor entity and for the characterization of the hormone excess syndromes. Recent developments in molecular biology have provided tools for testing for hereditary tumor syndromes associated with adrenal tumorigenesis and to establish strategies for further treatment and follow-up.

Entities:  

Mesh:

Year:  2007        PMID: 17684715     DOI: 10.1007/s00108-007-1907-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  25 in total

Review 1.  CLINICAL CHARACTERISTICS OF PRIMARY ALDOSTERONISM FROM AN ANALYSIS OF 145 CASES.

Authors:  J W CONN; R F KNOPF; R M NESBIT
Journal:  Am J Surg       Date:  1964-01       Impact factor: 2.565

2.  Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing Cushing's syndrome.

Authors:  H S Willenberg; C A Stratakis; C Marx; M Ehrhart-Bornstein; G P Chrousos; S R Bornstein
Journal:  N Engl J Med       Date:  1998-07-02       Impact factor: 91.245

3.  Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.

Authors:  Martin Fassnacht; Stefanie Hahner; Buelent Polat; Ann-Cathrin Koschker; Werner Kenn; Michael Flentje; Bruno Allolio
Journal:  J Clin Endocrinol Metab       Date:  2006-08-08       Impact factor: 5.958

Review 4.  Management of patients with adrenal cancer: recommendations of an international consensus conference.

Authors:  D E Schteingart; G M Doherty; P G Gauger; T J Giordano; G D Hammer; M Korobkin; F P Worden
Journal:  Endocr Relat Cancer       Date:  2005-09       Impact factor: 5.678

Review 5.  [Modern pharmacological aspects of hyperaldosteronism therapy].

Authors:  M Quinkler; M Reincke
Journal:  Internist (Berl)       Date:  2006-09       Impact factor: 0.743

6.  Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.

Authors:  C E Fardella; L Mosso; C Gómez-Sánchez; P Cortés; J Soto; L Gómez; M Pinto; A Huete; E Oestreicher; A Foradori; J Montero
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

7.  Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005.

Authors:  Karel Pacak; Graeme Eisenhofer; Håkan Ahlman; Stefan R Bornstein; Anne-Paule Gimenez-Roqueplo; Ashley B Grossman; Noriko Kimura; Massimo Mannelli; Anne Marie McNicol; Arthur S Tischler
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-02

Review 8.  [Adrenocortical tumours].

Authors:  W Saeger
Journal:  Pathologe       Date:  2003-05-06       Impact factor: 1.011

9.  Subclinical hormone secretion by incidentally discovered adrenal masses.

Authors:  R H Caplan; P J Strutt; G G Wickus
Journal:  Arch Surg       Date:  1994-03

10.  Surgical management, DNA content, and patient survival in adrenal cortical carcinoma.

Authors:  J E Lee; D H Berger; A K el-Naggar; R C Hickey; R Vassilopoulou-Sellin; R F Gagel; M A Burgess; D B Evans
Journal:  Surgery       Date:  1995-12       Impact factor: 3.982

View more
  1 in total

1.  [Adrenal tumors. Principles of diagnostics and operative treatment].

Authors:  A Gonsior; H Pfeiffer; D Führer; E Liatsikos; T Schwalenberg; J-U Stolzenburg
Journal:  Urologe A       Date:  2010-05       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.